EUVIMEDEUVIMED entdecken
Crossref

Cutaneous pseudolymphoma successfully treated with dupilumab

Shuji Sugiura, Takeshi Nakanishi, Noriki Fujimoto

European Journal of Dermatology · 2023

DOI: 10.1684/ejd.2023.4482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Shuji Sugiura und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Pseudolymphoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis itself, as well as its immunomodulatory drugs, may alter the immune system, increasing the risk of infections. Recent research has indicated that patients with psoriasis are at an increased risk of developing severe infections including tuberculosis.

Objectives

To evaluate and compare the incidence of serious infectious diseases in Korea between patients with psoriasis and participants without psoriasis regarding each treatment modality. Materials & Methods: This nationwide cohort study utilized claims data based on the National Health Insurance Service between January 2005 and December 2018.

Results

In total, 293,073 patients with psoriasis enrolled for the analysis of serious infection and 272,400 patients enrolled for the analysis of tuberculosis. Participants without psoriasis matched by age and sex (1:1 ratio) were also enrolled. For serious infection overall, the adjusted hazard ratios (aHRs) (95% confidence interval [CI]) were 1.21 (1.20–1.23), 1.23 (1.17–1.28), and 1.33 (1.09–1.63) for the non-systemic, non-biologic systemic, and biologic groups, respectively. For tuberculosis overall, the aHRs were 1.15 (1.10–1.20), 1.32 (1.10–1.57), and 6.72 (4.28–10.56) for the non-systemic, non-biologic systemic, and biologic groups, respectively.

Conclusion

This study reveals that the risk of serious infection and tuberculosis in patients with psoriasis was significantly higher than in participants without psoriasis. Moreover, patients with psoriasis who received systemic therapy other than phototherapy had a higher risk of these infections compared to those without psoriasis. Also, biologics appeared to increase the risk of tuberculosis in patients with psoriasis. Dermatologists should consider these potential risks when selecting treatment modalities for psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PseudolymphomaHumansAntibodies, Monoclonal, Humanized

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Zitieren

APA

Sugiura, S., Nakanishi, T., & Fujimoto, N. (2023). Cutaneous pseudolymphoma successfully treated with dupilumab. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4482

Vancouver

Sugiura S, Nakanishi T, Fujimoto N. Cutaneous pseudolymphoma successfully treated with dupilumab. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4482

BibTeX
@article{Sugiura2023,
  author = {Sugiura, Shuji and Nakanishi, Takeshi and Fujimoto, Noriki},
  title = {Cutaneous pseudolymphoma successfully treated with dupilumab},
  journal = {European Journal of Dermatology},
  year = {2023},
  doi = {10.1684/ejd.2023.4482}
}
Kostenlos starten →